<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327934</url>
  </required_header>
  <id_info>
    <org_study_id>2000020950</org_study_id>
    <nct_id>NCT04327934</nct_id>
  </id_info>
  <brief_title>Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome</brief_title>
  <official_title>Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women with androgen excess polycystic ovary syndrome (AE-PCOS) leads to hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our scientific premise is that in AE-PCOS women, the androgen-dominant hormonal milieu causes
      BP increases via sympathetic activation, vasoconstriction and renal sympathetic nervous
      system activation. Moreover, this androgen-dominant milieu increases BP via activation of the
      renin-angiotensin system.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baroreflex assessment</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>forearm blood flow (ultrasound)/mean arterial pressure as a linear function of lower body negative pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sympathetic response during LBNP</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Catecholamines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic blood pressure response to LBNP</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Beat by beat systolic blood pressure (Finometer)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic blood pressure response to LBNP</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Beat by beat diastolic blood pressure (Finometer)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sympathetic Baroreflex Assessment</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Sympathetic Nerve activity (microneurography) during modified Oxford. Measured as MSNA as a function of diastolic blood pressure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal response to LBNP</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Plasma renin activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paced Breathing</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Resting muscle sympathetic activity (MSNA) from nerves (microneurography in microvolts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baroreflex response</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Valsalva Maneuver. Muscle sympathetic outflow from nerves during small blood pressure changes (microneurography in microvolts)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy control participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AE-PCOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with AE-PCOS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH antagonist</intervention_name>
    <description>GnRH antagonist up to 16 days.</description>
    <arm_group_label>AE-PCOS</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH antagonist + MethylTESTOSTERone 5 MG</intervention_name>
    <description>GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.</description>
    <arm_group_label>AE-PCOS</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical Diagnosis of Polycystic Ovary Syndrome

          -  Able to inject study drug

          -  Able to swallow pills

        Controls:

        -Diagnosis of Insulin resistance

        Exclusion Criteria:

          -  Any woman that does not fit the inclusion criteria

          -  Males
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Obese Insulin Resistant (IR) women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Stachenfeld, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The John B Pierce Laboratory</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

